- Home
- BLAC vs ITRM Comparison
BLAC vs ITRM Comparison
Compare BLAC & ITRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BLAC
- ITRM
- Stock Information
- Founded
- BLAC 2020
- ITRM 2015
- Country
- BLAC United States
- ITRM Ireland
- Employees
- BLAC N/A
- ITRM N/A
- Industry
- BLAC
- ITRM Biotechnology: Pharmaceutical Preparations
- Sector
- BLAC
- ITRM Health Care
- Exchange
- BLAC NYSE
- ITRM Nasdaq
- Market Cap
- BLAC 26.3M
- ITRM 49.5M
- IPO Year
- BLAC 2023
- ITRM 2018
- Fundamental
- Price
- BLAC $11.42
- ITRM $1.56
- Analyst Decision
- BLAC
- ITRM Strong Buy
- Analyst Count
- BLAC 0
- ITRM 1
- Target Price
- BLAC N/A
- ITRM $5.00
- AVG Volume (30 Days)
- BLAC 6.2K
- ITRM 632.4K
- Earning Date
- BLAC 01-01-0001
- ITRM 02-07-2025
- Dividend Yield
- BLAC N/A
- ITRM N/A
- EPS Growth
- BLAC N/A
- ITRM N/A
- EPS
- BLAC N/A
- ITRM N/A
- Revenue
- BLAC N/A
- ITRM N/A
- Revenue This Year
- BLAC N/A
- ITRM N/A
- Revenue Next Year
- BLAC N/A
- ITRM N/A
- P/E Ratio
- BLAC N/A
- ITRM N/A
- Revenue Growth
- BLAC N/A
- ITRM N/A
- 52 Week Low
- BLAC $10.56
- ITRM $0.81
- 52 Week High
- BLAC $13.40
- ITRM $3.02
- Technical
- Relative Strength Index (RSI)
- BLAC 50.56
- ITRM 42.70
- Support Level
- BLAC $11.27
- ITRM $1.47
- Resistance Level
- BLAC $11.50
- ITRM $1.75
- Average True Range (ATR)
- BLAC 0.31
- ITRM 0.10
- MACD
- BLAC -0.02
- ITRM 0.01
- Stochastic Oscillator
- BLAC 14.86
- ITRM 27.59
About BLAC BELLEVUE LIFE SCIENCES ACQ CORP
Bellevue Life Sciences Acquisition Corp is a blank check company.
About ITRM Iterum Therapeutics plc
Iterum Therapeutics PLC is a clinical-stage pharmaceutical company. The company is engaged in developing and commercializing sulopenem to be the first and only oral and intravenous branded penem available globally. Its sulopenem program has the potential to offer a solution to the problem of antibiotic resistance and the toxicity limitations of existing agents. The company operates as a single business segment, which is the development and commercialization of treatments for drug-resistant bacterial infections.